CD274 and small cell lung carcinoma: A Phase II trial also demonstrated an acceptable safety profile of SHR-1316 (programmed cell death-ligand 1 antibody) in combination with chemotherapy and sequential TRT as first-line treatment for ES-SCLC [25].